Azevedo Fabiula Schwartz, Correa Marcelo Goulart, Paula Débora Holanda Gonçalves, Felix Alex Dos Santos, Belém Luciano Herman Juaçaba, Mendes Ana Paula Chedid, Silva Valeria Gonçalves, Marques Bruno Miranda, Monteiro Andrey José de Oliveira, Weksler Clara, Colafranceschi Alexandre Siciliano, Kasal Daniel Arthur Barata
Instituto Nacional de Cardiologia (INC), Rio de Janeiro, RJ, Brazil.
Braz J Cardiovasc Surg. 2018 Jan-Feb;33(1):1-7. doi: 10.21470/1678-9741-2017-0117.
Transcatheter aortic valve replacement has been an alternative to invasive treatment for symptomatic severe aortic stenosis in high risk patients. The primary endpoint was 30-day and 1-year mortality from any cause. Secondary endpoints were to compare the clinical and echocardiographic variation pre-and post- transcatheter aortic valve replacement, and the occurrence of complications throughout a 4-year follow-up period.
This prospective cohort, nestled to a multicenter study (Registro Brasileiro de Implante de Bioprótese por Cateter), describes the experience of a public tertiary center in transcatheter aortic valve replacement. All patients who underwent this procedure between October 2011 and February 2016 were included.
Fifty-eight patients underwent transcatheter aortic valve replacement. The 30-day all-cause mortality was 5.2% (n=3) and after 1 year was 17.2% (n=10). A significant improvement in New York Heart Association functional classification was observed when comparing pre-and post- transcatheter aortic valve replacement (III or IV 84.4% versus 5.8%; P<0.001). A decline in peak was observed (P<0.001) and mean (P<0.001) systolic transaortic gradient. The results of peak and mean post-implant transaortic gradient were sustained after one year (P=0.29 and P=0.36, respectively). Left ventricular ejection fraction did not change significantly during follow-up (P=0.41). The most frequent complications were bleeding (28.9%), the need for permanent pacemaker (27.6%) and acute renal injury (20.6%).
Mortality and complications in this study were consistent with worldwide experience. Transcatheter aortic valve replacement had positive clinical and hemodynamic results, when comparing pre-and post-procedure, and the hemodynamic profile of the prosthesis was sustained throughout follow-up.
经导管主动脉瓣置换术已成为高危患者有症状的严重主动脉瓣狭窄侵入性治疗的替代方法。主要终点是30天和1年的全因死亡率。次要终点是比较经导管主动脉瓣置换术前和术后的临床及超声心动图变化,以及4年随访期内并发症的发生情况。
本前瞻性队列研究嵌套于一项多中心研究(巴西经导管生物假体植入登记研究),描述了一家公立三级中心经导管主动脉瓣置换术的经验。纳入了2011年10月至2016年2月期间接受该手术的所有患者。
58例患者接受了经导管主动脉瓣置换术。30天全因死亡率为5.2%(n = 3),1年后为17.2%(n = 10)。比较经导管主动脉瓣置换术前和术后,纽约心脏协会功能分级有显著改善(III或IV级从84.4%降至5.8%;P < 0.001)。观察到峰值(P < 0.001)和平均(P < 0.001)跨主动脉收缩期梯度下降。植入后1年,峰值和平均跨主动脉梯度结果保持稳定(分别为P = 0.29和P = 0.36)。随访期间左心室射血分数无显著变化(P = 0.41)。最常见的并发症是出血(28.9%)、需要永久起搏器(27.6%)和急性肾损伤(20.6%)。
本研究中的死亡率和并发症与全球经验一致。经导管主动脉瓣置换术在比较术前和术后时具有积极的临床和血流动力学结果,并且假体的血流动力学特征在整个随访期间保持稳定。